BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jessica Fye
JPMorgan Chase & Co, Research Division

Great. Good afternoon. Welcome, everyone. My name is Jess Fye. I’m a biotech analyst at JPMorgan, and we’re continuing our 44th Annual Healthcare Conference today with BioNTech.

First, you’re going to hear a presentation from the company, and then we’re going to go into some Q&A. So if you have a question in the room, just raise your hand and someone will bring you a microphone or alternatively, you can submit it online, and I’ll read it off the iPad up here.

So with that out of the way, I’m pleased to introduce BioNTech’s CEO, Ugur Sahin.

Ugur Sahin
Co-Founder, CEO & Chair of the Management Board

Hello, everyone. It’s a pleasure to be here. I would like to welcome everyone here and online. These are the typical disclaimers. And I would like to start with the — can we just change what is on the monitor?

Okay. So let me start with the status quo that we have here. While BioNTech has grown and evolved, our vision has remained the same, namely translating science into survival. From the current situation, from today’s perspective, we have so far delivered together with our partner, Pfizer, 5 billion doses of vaccines worldwide. We have engaged with our mRNA technology in global health programs, have 6 programs here running. Most importantly, we pivoted back to oncology, have currently 25 clinical trials ongoing and 16 clinical programs. We have also integrated AI and advanced GMP manufacturing capabilities, providing us the opportunity to rapidly translate science into clinical trials.